24 January 2024
24 January 2024
EraCal is entitled to receive €235m ($256.09m) in upfront, development and commercial milestone payments.
The company ceased activity for its CKD program to sharpen its clinical focus in the Phase II/III program for notalgia paresthetica.
Genentech will utilise GenEdit’s non-viral polymer nanoparticles for gene therapy delivery in autoimmune diseases.
The funds will be used to advance the development of the company’s lead programmes, DHX9 and KIF18A inhibitors.
ISAB's strategic shift towards services as its primary revenue source is further supported by the partnership.
The company has four monoclonal antibody candidates in the pipeline under development for inflammatory and fibrotic diseases.
The company could be in line for a priority review voucher if 4D-710, currently in Phase I/II clinical trials, is approved.
NAYA’s acquisition includes Florida Biotechnologies’ AAV gene therapy for the treatment of a rare genetic disorder.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
